Erratum: Clopidogrel: Review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies (Biomedical Chromatography (2009) vol. 23, (1) (26-41) 10.1002/bmc.1128);Clopidogrel: Review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies

Biomedical Chromatography

Volumn 23, Issue 1, 2009, Pages 26-41

  Mullangi, Ramesh ^a   Srinivas, Nuggehally R ^b  

^a DR REDDY'S LABORATORIES LTD   (India)

^b ClinTec   (India)

Author keywords

Bioanalytical; Cardiovascular; Clopidogrel; Interaction; Metabolite; Pharmacodynamics; Pharmacokinetics; Validation

Indexed keywords

BIOMOLECULES; DISEASES; DRUG INTERACTIONS; PHARMACOKINETICS;

BIOANALYTICAL; BIOANALYTICAL METHODS; CARDIOVASCULAR; CLOPIDOGREL; DRUG-DRUG INTERACTIONS; INTERACTION; INTERACTION STUDIES; PROPERTY; RECENT TRENDS; VALIDATION;

METABOLITES;

2 (2 CHLOROPHENYL) 2 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)ACETIC ACID; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATORVASTATIN; CARBOXYLIC ACID; CERIVASTATIN; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A5; DIGOXIN; DONEPEZIL; DRUG METABOLITE; ERYTHROMYCIN; FLUINDOSTATIN; KETOCONAZOLE; LANSOPRAZOLE; PLACEBO; PRASUGREL; PRAVASTATIN; REPAGLINIDE; RIFAMPICIN; SIMVASTATIN; THEOPHYLLINE; TICLOPIDINE; TROLEANDOMYCIN; WARFARIN;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HUMAN; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SMOKING; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TIME TO MAXIMUM PLASMA CONCENTRATION; WISTAR RAT;

EID: 59949086939     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1210     Document Type: Erratum

References (56)

1. Ayalasomayajula SP, Vaidyanathan S, Kemp C, Prasad P, Balch A and Dole WP. Effect of clopidogrel on the steady state pharmacokinetics of fluvastatin. Journal of Clinical Pharmacology 2007; 47: 613-619.
2. Bahrami G, Mohammadi B and Sisakhtnezhad S. High performance liquid chromatographic determination of inactive carboxylic acid metabolite of clopidogrel in human serum: Application to a bioequivalence study. Journal of Chromatography B 2008; 864: 168-172.
3. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D and Winters KJ. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel not prasugrel. Journal of Thrombosis and Hemostasis 2007; 5: 2429-2436.
4. Caplain H, Donat F, Gaud C and Necciari J. Pharmacokinetics of clopidogrel. Seminars in Thrombosis and Hemostasis 1999a; 25: 25-28.
5. Caplain H, Thebault JJ and Necciari J. Clopidogrel does not affect the pharmacokinetics of theophylline. Seminars in Thrombosis and Hemostasis 1999b; 25: 65-68.
6. CAPRIE Steering Committee. A randomized, blinded, trial of SR25990C versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
7. Clarke TA and Waskell TA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metabolism and Disposition 2003; 31: 53-59.
8. Delaney JA, Opatrny L, Brophy JM and Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. Canadian Medical Association Journal 2007; 14: 347-351.
9. Diener HC, Ringleb PA and Savi P. Clopidogrel for the secondary prevention of stroke. Expert Opinion n Pharmacotherapy 2005; 6: 755-764.
10. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA and Salazar DE. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clinical Pharmacology and Therapeutics 2007; 81: 735-741.
11. Fox KA and Chelliah R. Clopidogrel: an updated and comprehensive review. Expert Opinion Drug Metabolsim and Toxicology 2007; 3: 621-631.
12. Gardell SJ. The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk. Toxicology Pathology 1993; 21: 190-198.
13. Geiger J, Brich J, Honig-Liedl P, Eigenthaler M, Schanzenbacher P, Herbert JM and Walter U. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arteriosclerosis, Thrombosis and Vascular Biology 1999; 19: 2007-2011.
14. Heestermans AACM, Van Werkum JW, Schomig E, Ten Berg JM and Taubert D. Clopidogrel resistance caused by a failure to metabolize clopidogrel into its metabolites. Journal of Thrombosis and Hemostasis 2006; 4: 1143-1145.
15. Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger Y, Necciari J, Defreyn G and Maffrand JP. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovascular Reviews 1993; 11: 180-198.
16. Hermosillo AJ and Spinler SA. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? Annals of Pharmacotherapy 2008; 42: 790-805.
17. Ki MH, Choi MH, Ahn KB, Kim BS, Im DS, Ahn SK and Hin HJ. The efficacy and safety of clopidogrel resinate as a novel polymeric salt form of clopidogrel. Archives of Pharmaceutical Research 2008; 31: 250-258.
18. Kim KA, Park PW and Park JY. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. European Journal of Clinical Pharmacology 2008a; 64: 589-597.
19. Kim KA, Park P, Hong S and Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clinical Pharmacology and Therapeutics 2008b; 84: 236-242.
20. Ksycinska H, Rudzki P and Bukowska-Kiliszek M. Determination of clopidogrel metabolite (SR26334) in human by LC-MS. Journal of Pharmaceutical and Biomedical Analysis 2006; 41: 533.
21. Lagorce P, Perez Y, Ortiz J, Necciari J and Bressolle F. Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography-mass spectrometry. Journal of Chromatography B 1998; 720: 107.
22. Lainesse A, Ozalp Y, Wong H and Alpan RS. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung 2004; 54: 618-624.
23. Lau WC and Gurbel PA. Antiplatelet drug resistance and drug-drug interactions: role of cytochrome P450 3A4. Pharmaceutical Research 2006; 23: 2691-2708.
24. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DGM, Guyer KE and Bates ER. Atorvastatin reduced the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-37.
25. 14C-labeled clopidogrel. Seminars in Thrombosis and Hemostasis 1999; 25: 29-33.
26. Mani H, Toennes SW, Linnemann B, Urbanek DA, Schwonberg J, Kauert GF, Lindhoff-Last E. Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy? Therapeutic Drug Monitoring 2008; 30: 84-89.
27. Mills DC, Puri R, Hu CJ, Minnity C, Grana G, Freedman MD, Colman RF and Colman RW. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arteriosclerosis and Thrombosis 1992; 2: 430-436.
28. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA and Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acure coronary syndromes. Circulation 2004; 109: 1335-1338.
29. Muller I, Besta F, Schulz C, Li Z, Massberg S and Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003; 108: 2195-2197.
30. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M and Mugge A. Lipophilic statins interfere with inhibitory effects of clopidogrel on platelet function - a flow cytometry study. European Heart Journal 2003; 24: 1744-1749.
31. Nirogi RVS, Kandikere VN, Shukla M, Mudigonda K, Maurya S and Boosi R. Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2006a; 20: 1695.
32. Nirogi RV, Kandikere VN and Mudigonda K. Effect of food on bioavailability of a single dose of clopidogrel in healthy male subjects. Arzneimittelforschung 2006b; 56: 735-739.
33. Peeters PA, Crijns HJ, Tamminga WJ, Jonkman JH, Dickinson JP and Necciari J. Clopidogrel, a novel antiplatlet agent, and digoxin: absence of pharmacodynamic and pharmacokinetic interaction. Seminars in Thrombosis and Hemostasis 1999; 25: 51-54.
34. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP and Picard C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metabolism and Disposition 2002; 30: 1288-1295.
35. Rao TRK, Usha PR, Naidu MUR, Gogtay JA and Meena M. Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Current Therapeutic Research 2003; 64: 685-696.
36. Reist M, Roy-De Vos M, Montseny J-P, Mayer JM, Carrupt P-A, Berger Y and Testa B. Very slow chiral inversion of clopidogrel in rats: a pharmacokinetic and mechanistic investigation. Drug Metabolism and Disposition 2000; 28: 1405-1410.
37. Robinson A, Hills J, Neal C and Leary AC. The validation of a bioanalytical method for the determination of clopidogrel in human plasma. Journal of Chromatography B 2007; 848: 344.
38. Savi P and Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Seminars in Thrombosis and Haemostasis 2005; 31: 174-183.
39. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G and Maffrand JP. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochemical Pharmacology 1992; 44: 527-532.
40. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y and Herbert JM. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thrombosis Haemostasis 1994; 72: 313-317.
41. Savi P, Pflieger AM and Herbert JM. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagulation and Fibrinolysis 1996; 7: 249-252.
42. Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Hervé C, Uzabiaga MF, Pereillo JM, Culouscou JM, Bono F, Ferrara P and Herbert JM. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proceedings of National Academy of Science USA 2006; 103: 11069-11074.
43. Saw J, Steinhubl SR, Berger PB, Kereiakes D, Serebruany VL, Brennan D and Topol EJ. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-924.
44. Shin BS and Yoo SD. Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. Biomedical Chromatography 2007; 21: 883-889.
45. Slugg PH, Much DR, Smith WB, Vargas R, Nichola P and Necciari J. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. Journal of Clinical Pharmacology 2000; 40: 396-401.
46. Singh SS, Sharma K, Barot D, Ram Mohan P and Lohray VB. Estimation of carboxylic acid metabolite of clopidogrel in wistar rat plasma by HPLC and its application to a pharmacokinetic study. Journal of Chromatography B 2005; 821: 173.
47. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE and Winters KJ. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Journal of Clinical Pharmacology 2008; 48: 475-484.
48. Souri E, Jalalizadeh H, Kebriaee-Zadeh A, Shekarchi M and Dalvandi A. Validated method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. Biomedical Chromatography 2006; 20: 1309.
49. Taubert D, Kastrati A, Harlfinger S, Gorchakoca O, Lazar A, von Beckerath N, Schomig A and Schomig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thrombosis and Haemostasis 2004; 92: 311-316.
50. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schoming A and Schomig E. Impact of P-glycoprotein on clopidogrel absorption. Clinical Pharmacology and Therapeutics 2006; 80: 486-501.
51. Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect harmacokinetics and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects. Journal of Thrombosis and Haemostasis 2008.
52. Von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A and Schomig A. Absorption, metabolization and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: chosen between 3 high oral doses for immediate clopidogrel effect) trial. Circulation 2005; 112: 2946-2950.
53. Wada M, Nishiwaki J, Yamane T, Ohwaki Y, Aboul-Enein HY and Nakashima K. Interaction study of aspirin or clopidogrel on pharmacokinetics of donezepil hydrochloride in rats by HPLC-fluorescence detection. Biomedical Chromatography 2007; 21: 616-620.
54. Wenaweser P, Windecker S, Billinger M, Cook S, Togni M, Meier B, Haeberli A and Hess OM. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. American Journal of Cardiology 2007; 99: 353-356.
55. Wienbergen H. Gitt AK, Schiele R, Juenger C, Heer T, Meisenzahl C, Limbourg P, Bossaller C and Senges J. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. The American Journal of Cardiology 2003; 92: 285-288.
56. Yousef AM, Arafat T, Bulatova NR and Al-Zumyli R. Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. Journal of Clinical Pharmacology and Therapeutics 2008; 33: 439-449.